文献速递腹部MR

慢性肝病的定量磁共振成像

Quantitative magnetic resonance imaging for chronic liver disease.
PubMed 文献 · Br J Radiol · 2021-02-26

本综述概述肝活检作为慢性肝病诊断、严重度评估和纵向监测金标准的局限性,并讨论基于MRI的肝铁、脂肪、纤维化和炎症生物标志物的当前最新进展,这些无创定量生物标志物可克服活检的局限。

要点

  • MRI定量生物标志物可无创评估肝铁、脂肪、纤维化和炎症。
  • 肝活检虽是临床金标准,但存在局限性,可能不适合临床和研究场景。
  • MRI定量评估可提供准确、精确的慢性肝病关键组分测量。

局限性

  • 肝活检作为临床金标准存在局限性,可能使其在临床和研究场景中并非最优。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Chronic liver disease (CLD) has rapidly increased in prevalence over the past two decades, resulting in significant morbidity and mortality worldwide. Historically, the clinical gold standard for diagnosis, assessment of severity, and longitudinal monitoring of CLD has been liver biopsy with histological analysis, but this approach has limitations that may make it suboptimal for clinical and research settings. Magnetic resonance (MR)-based biomarkers can overcome the limitations by allowing accurate, precise, and quantitative assessment of key components of CLD without the risk of invasive procedures. This review briefly describes the limitations associated with liver biopsy and the need for non-invasive biomarkers. It then discusses the current state-of-the-art for MRI-based biomarkers of liver iron, fat, and fibrosis, and inflammation.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Moura Cunha G, Navin PJ, Fowler KJ, et al. Quantitative magnetic resonance imaging for chronic liver disease. Br J Radiol. 2021. PMID: 33635729. doi:10.1259/bjr.20201377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。